Naporafenibum is under clinical development by Erasca and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Naporafenibum’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Naporafenibum (LXH-254) is under development for the treatment of advanced unresectable or metastatic solid tumor, metastatic melanoma, metastatic colorectal cancer, colon cancer, non small cell lung cancer. The drug candidate is administered orally. It acts by targeting pan RAF kinase. It is a new molecular entity (NME).
Erasca is an oncology drug development company that uses its artificial intelligence drug discovery platform to treat and cure cancer. The company is headquartered in San Diego, California, the US.
For a complete picture of Naporafenibum’s drug-specific PTSR and LoA scores, buy the report here.